TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood: Interventional Trial in the COPSAC2010 (Copenhagen Studies on Asthma in Childhood) Birth Cohort
Brief Summary: The aim of this study is to prevent asthma and allergies in childhood by supplementation with fish oil (n-3 fatty acids) to the mother during pregnancy. Paticipants are mother and children participating in the ABC-(Asthma Begins in Childhood)cohort. Mothers are recruited during pregnancy and receive supplement with n-3 fatty acids or olive oil (placebo) from week 24 of gestation to 1 week after delivery. The child is followed with acute and planned visit at the research unit and diagnosis of disease is done in the research unit according to predefined algorithms.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA Supplements | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA Supplements; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Supplements; Assigned to Arm(s): 2
B: Arm Label: Fish-Oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Fish oil, Ocean plus | Arm Label: Sunflower oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sunflower Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil, Ocean plus; Assigned to Arm(s): Fish-Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Sunflower Oil; Assigned to Arm(s): Sunflower oil
C: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: n-3 fatty acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: n-3 fatty acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: olive oil; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion.
Brief Summary: This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. In previously performed clinical trials, some patients treated with intravitreal microplasmin have had resolution of their underlying condition, including macular hole closure, without need for vitrectomy. This clinical trial is justified because the sponsor believes the potential benefits outweigh the potential risks.


Options:
A: Arm Label: Ocriplasmin 125µg; Type: EXPERIMENTAL; Interventions: Drug: Ocriplasmin 125µg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ocriplasmin 125µg; Assigned to Arm(s): Ocriplasmin 125µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: macular hole operation no peeling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Macular hole operation ICG peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: macular hole operation | Arm Label: Macular hole operation TB peeling; Type: EXPERIMENTAL; Interventions: Procedure: macular hole operation | Intervention Type: PROCEDURE; Name: macular hole operation; Assigned to Arm(s): Macular hole operation ICG peeling, Macular hole operation TB peeling
C: Arm Label: ILM peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel. | Arm Label: No ILM peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel. | Intervention Type: PROCEDURE; Name: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.; Assigned to Arm(s): ILM peeling, No ILM peeling
D: Arm Label: 125µg Ocriplasmin; Type: EXPERIMENTAL; Interventions: Drug: 125 µg Ocriplasmin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 125 µg Ocriplasmin; Assigned to Arm(s): 125µg Ocriplasmin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder.
Brief Summary: The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment. It is postulated that this drug will also prove effective in elderly patients (aged \> 65 years) and that the ability to change dose between 4 and 8mg will allow each patient to have an optimised treatment.


Options:
A: Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fesoterodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fesoterodine fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fesoterodine fumarate; Assigned to Arm(s): Fesoterodine
B: Arm Label: I.Solifenacin succinate 10mg (2x5mg 1/day); Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate | Arm Label: II.Solifenacin succinate 5mg (5mg 1/day); Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate | Arm Label: III.Oxybutynin hydrochloride 15mg (5mg 3/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin Hydrochloride | Arm Label: IV. Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): I.Solifenacin succinate 10mg (2x5mg 1/day) | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): II.Solifenacin succinate 5mg (5mg 1/day) | Intervention Type: DRUG; Name: Oxybutynin Hydrochloride; Assigned to Arm(s): III.Oxybutynin hydrochloride 15mg (5mg 3/day) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV. Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: DA-8010 Placebo, Drug: Solifenacin succinate placebo | Arm Label: DA-8010 2.5mg; Type: EXPERIMENTAL; Interventions: Drug: DA-8010 2.5mg, Drug: Solifenacin succinate placebo | Arm Label: DA-8010 5mg; Type: EXPERIMENTAL; Interventions: Drug: DA-8010 5mg, Drug: Solifenacin succinate placebo | Arm Label: Solifenacin 5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: DA-8010 Placebo, Drug: Solifenacin 5mg | Intervention Type: DRUG; Name: DA-8010 Placebo; Assigned to Arm(s): Placebo, Solifenacin 5mg | Intervention Type: DRUG; Name: DA-8010 2.5mg; Assigned to Arm(s): DA-8010 2.5mg | Intervention Type: DRUG; Name: DA-8010 5mg; Assigned to Arm(s): DA-8010 5mg | Intervention Type: DRUG; Name: Solifenacin 5mg; Assigned to Arm(s): Solifenacin 5mg | Intervention Type: DRUG; Name: Solifenacin succinate placebo; Assigned to Arm(s): DA-8010 2.5mg, DA-8010 5mg, Placebo
D: Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial
Brief Summary: The purpose of this study is to test the hypotheses that argatroban significantly increases efficacy and safety of renal replacement therapy measured as life time of haemodialysis filters as compared to lepirudin


Options:
A: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2
B: Arm Label: Femoral route; Type: EXPERIMENTAL; Interventions: Procedure: Femoral route for hemodialysis | Arm Label: Jugular route; Type: EXPERIMENTAL; Interventions: Procedure: Jugular route for hemodialysis | Intervention Type: PROCEDURE; Name: Femoral route for hemodialysis; Assigned to Arm(s): Femoral route | Intervention Type: PROCEDURE; Name: Jugular route for hemodialysis; Assigned to Arm(s): Jugular route
C: Arm Label: oXiris as first filter; Type: ACTIVE_COMPARATOR; Interventions: Device: oXiris as first filter | Arm Label: M150 as first filter; Type: OTHER; Interventions: Device: M150 as first filter | Intervention Type: DEVICE; Name: oXiris as first filter; Assigned to Arm(s): oXiris as first filter | Intervention Type: DEVICE; Name: M150 as first filter; Assigned to Arm(s): M150 as first filter
D: Arm Label: Heparin lock; Type: PLACEBO_COMPARATOR; Interventions: Drug: unfractionated heparin | Arm Label: Citrate lock; Type: EXPERIMENTAL; Interventions: Drug: Citrate 4% | Intervention Type: DRUG; Name: Citrate 4%; Assigned to Arm(s): Citrate lock | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): Heparin lock

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial
Brief Summary: The purpose of this study is to test the hypotheses that argatroban significantly increases efficacy and safety of renal replacement therapy measured as life time of haemodialysis filters as compared to lepirudin


Options:
A: Arm Label: Prismocitrate 18; Type: EXPERIMENTAL; Interventions: Drug: Prismocitrate 18 | Arm Label: No Regional Anticoagulation of CRRT Circuit; Type: ACTIVE_COMPARATOR; Interventions: Other: No Anticoagulation | Intervention Type: DRUG; Name: Prismocitrate 18; Assigned to Arm(s): Prismocitrate 18 | Intervention Type: OTHER; Name: No Anticoagulation; Assigned to Arm(s): No Regional Anticoagulation of CRRT Circuit
B: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
C: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2
D: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial
Brief Summary: The purpose of this study is to test the hypotheses that argatroban significantly increases efficacy and safety of renal replacement therapy measured as life time of haemodialysis filters as compared to lepirudin


Options:
A: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
B: Arm Label: Heparin lock; Type: PLACEBO_COMPARATOR; Interventions: Drug: unfractionated heparin | Arm Label: Citrate lock; Type: EXPERIMENTAL; Interventions: Drug: Citrate 4% | Intervention Type: DRUG; Name: Citrate 4%; Assigned to Arm(s): Citrate lock | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): Heparin lock
C: Arm Label: Standard Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Citrasate; Type: EXPERIMENTAL; Interventions: Drug: Citrasate | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Standard Anticoagulation | Intervention Type: DRUG; Name: Citrasate; Assigned to Arm(s): Citrasate
D: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (25 and 50 mg/Day) of DVS SR Tablets in Adult Outpatients With Major Depressive Disorder
Brief Summary: The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.


Options:
A: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: desvenlafaxine succinate sustained release | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Genetic: Genotyping | Intervention Type: DRUG; Name: desvenlafaxine succinate sustained release; Assigned to Arm(s): 1 | Intervention Type: GENETIC; Name: Genotyping; Assigned to Arm(s): 2
C: Arm Label: Desvenlafaxine succinate sustained-release 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 25 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Care manager for depression; Type: EXPERIMENTAL; Interventions: Other: care manager for depression | Arm Label: Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: care manager for depression; Assigned to Arm(s): Care manager for depression

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Control Clinical Trial Of Micronutrient & Antioxidant Supplementation in Persons With Untreated HIV Infection
Brief Summary: Infection with human immunodeficiency virus (HIV) causes decline in immunity or the ability to fight infection and progresses to acquired immunodeficiency disease (AIDS). Anti-HIV drug treatment has improved the prognosis of persons with HIV infection, but is expensive and potentially toxic. Low micronutrient levels occur in the blood even in early stages of HIV infection and increase risk of a poorer prognosis, but the role of micronutrient and antioxidant supplements in medical management of HIV/AIDS is not well defined. The proposed clinical trial aims to assess if supplementation of untreated HIV-infected adults with a micronutrient and antioxidant preparation can delay decline in immunity or disease progression or start of anti-HIV drug treatment compared with supplementation with standard multivitamins. If the findings are positive, the study has implications for health and health care savings.


Options:
A: Arm Label: Multivitamins (B,C,E); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin supplements B,C and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Multivitamin supplements B,C and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplements B,C and E; Assigned to Arm(s): Multivitamins (B,C,E), Placebo
B: Arm Label: A: Broad spectrum micronutrients; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrients and antioxidants | Arm Label: B: Identical appearing multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins and minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrients and antioxidants; Assigned to Arm(s): A: Broad spectrum micronutrients | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins and minerals; Assigned to Arm(s): B: Identical appearing multivitamins
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Vitamin D 4000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): Vitamin D 4000 IU | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Multiple RDA multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins (including B, C and E) | Arm Label: Single RDA Multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins B, C and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins (including B, C and E); Assigned to Arm(s): Multiple RDA multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins B, C and E; Assigned to Arm(s): Single RDA Multivitamins

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial of Percutaneous Transluminal Angioplasty (PTA) Versus a Supervised Exercise Programme (SEP) in the Management of Intermittent Claudication (IC) Due to Femoro-popliteal Disease
Brief Summary: Intermittent Claudication (IC)is a common condition characterised by pain in the muscles of the legs on exertion caused by "hardening of the arteries" and a reduced blood supply. The investigators know that the vast majority of people suffering from this condition remain stable and do not deteriorate, and thus in general the viability of legs is not at risk. The main aim of treatment, therefore, is to try and improve walking thus reducing the impact this problem has on patients life style. There are many methods of management of intermittent claudication, but the investigators do not know which produces the best results. This study aims to compare the short and medium term outcomes of exercise programmes, percutaneous transluminal angioplasty and a combination of the two treatments for patients with intermittent claudication.


Options:
A: Arm Label: Angioplasty / surgery and exercise therapy; Type: EXPERIMENTAL; Interventions: Procedure: Angioplasty / surgery and exercise therapy | Arm Label: Angioplasty / surgery; Type: NO_INTERVENTION; Interventions: Procedure: angioplasty / surgery | Intervention Type: PROCEDURE; Name: angioplasty / surgery; Assigned to Arm(s): Angioplasty / surgery | Intervention Type: PROCEDURE; Name: Angioplasty / surgery and exercise therapy; Assigned to Arm(s): Angioplasty / surgery and exercise therapy
B: Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): N/A
C: Arm Label: PTA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Supervised Exercise Programme (SEP) | Arm Label: PTA+SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Combined Treatment | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): PTA | Intervention Type: PROCEDURE; Name: Supervised Exercise Programme (SEP); Assigned to Arm(s): SEP | Intervention Type: PROCEDURE; Name: Combined Treatment; Assigned to Arm(s): PTA+SEP
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Self-managed walking | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Self-managed walking; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD
Brief Summary: The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder (ADHD), when compared to placebo.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Quillivant Oral Suspension XR, Drug: Placebo | Arm Label: Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Quillivant Oral Suspension XR; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Comparator
B: Arm Label: ADHD; Type: N/A; Interventions: N/A
C: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CONCERTA (methylphenidate HCl) / Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Placebo/ CONCERTA (methylphenidate HCl) | Intervention Type: DRUG; Name: Placebo/ CONCERTA (methylphenidate HCl); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CONCERTA (methylphenidate HCl) / Placebo; Assigned to Arm(s): 1

Answer: D